e11622 Background: Hereditary BC can have a distinct phenotype and behavior in comparison to sporadic BC. The aim of the present study was to investigate if there is any difference in the age at diagnosis, disease extension and biological profile in BC patients (pts) with or without a significant family history of BC. Methods: We retrospectively reviewed clinical charts of BC pts, stage 0- III who had surgery between March 2006 and March 2008. We included pts with known estrogen receptor (ER), progesterone receptor (PR) and HER2 status. The family history was obtained from the clinical charts and confirmed by a telephone interview with a standardized questionnaire. A significant family history of BC was defined by the presence of one of the following criteria: (1) 3 or more BC cases among close relatives, at least one diagnosed before 50 years (2) 2 BC cases among close relatives, at least one diagnosed before 50 years and one of the following: bilateral BC, ovarian cancer diagnosed in the family, male BC, father´s inheritance, Ashkenazi Jewish ancestry Results: 435 pts were identified, with available data on ER/PR and HER2 status in 197 pts. Family history was evaluated in 136 pts (69%) and was classified as significant in 18 (13.2%). Between pts with and without a significant family history of BC cancer there were no difference in the proportion of pts < 50 years old at diagnosis (0.36 vs. 0.39), T3/T4 tumours (0.08 vs. 0.11), axillary node positivity (0.55 vs 0.66), ER/PR+ (0.77 vs. 0.72), HER2 + (0.11 vs. 0.11) and triple negative tumors (0.19 vs 0.17). Conclusions: our data does not show any difference in the main prognostic and predictive factors between operable BC pts with and without a significant family history of BC. These findings are concordant with previous published data about a greater prevalence of BRCA2 mutations in Uruguayan families. No significant financial relationships to disclose.
Objetivo: Analisar a Doença hemolítica do recém-nascido (DHRN) e suas repercussões na saúde materno-infantil. Revisão bibliográfica: A DHRN é uma condição na qual a gestante, já sensibilizada com aloantígenos, produz anticorpos contra as hemácias do feto, ocorrendo nos casos de incompatibilidade pelo sistema ABO ou Rh em sua maioria. Os anticorpos produzidos pela mãe são majoritariamente do tipo anti-D, sendo que apenas a classe IgG atravessa a barreira hematoplacentária e causa a doença. Para diagnóstico, deve ser feito estudo da tipagem sanguínea materna e paterna, ultrassom obstétrico e dopplervelocimetria fetal. Quando a doença é de caráter leve-moderado, não há grandes repercussões e a terapêutica pode ser realizada com um bom prognóstico; entretanto quando um estado grave se instala, com desenvolvimento de Kernicterus e hidropisia, o tratamento se torna mais complexo e custoso. Considerações finais: Por se tratar de uma doença evitável na maioria dos casos por meio da profilaxia pela imunoglobulina anti-D é recomendado sua utilização de forma adequada a fim de reduzir o aparecimento da doença e suas complicações.
Predicting disease at an early stage becomes critical, and the most difficult challenge is to predict it correctly along with the sickness. The prediction happens based on the symptoms of an individual. The model presented can work like a digital doctor for disease prediction, which helps to timely diagnose the disease and can be efficient for the person to take immediate measures. The model is much more accurate in the prediction of potential ailments. The work was tested with four machine learning algorithms and got the best accuracy with Random Forest.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.